BRIEF—Astellas and Kotobuki broaden label for Suglat in Japan

Astellas Pharma and Kotobuki Pharmaceutical have won approval in Japan for a new indication for Suglat (ipragliflozin L-Proline), to cover treatment of type 1 diabetes.

The therapy, a a selective SGLT2 inhibitor, was approved for type 2 diabetes in January 2014. It has been estimated that around 10 million people in Japan are very likely to have diabetes, with type 1 diabetes accounting for around 6% of the patient population.